Introduction#

Chugai Pharmaceutical Co., Ltd. has announced solid financial results for the first quarter of fiscal year 2026, showcasing significant growth in both revenue and profit. Despite these positive results, the company's stock experienced a minor decline in after-hours trading, indicating some caution among investors.

Company Performance#

In Q1 2026, Chugai's total revenue reached JPY 321.7 billion, reflecting an 11.5% increase compared to the same period last year. This growth was largely fueled by strong sales of key products like Hemlibra and Nemluvio, along with increased royalty income from Galderma. The company also reported a net income after tax of JPY 118.6 billion, which is a 19.6% rise year-over-year. Chugai's operating margin stood at a robust 52.8%, indicating effective cost management and profitability.

Financial Highlights#

  • Revenue: JPY 321.7 billion, up 11.5% year-over-year
  • Core Operating Profit: JPY 163.3 billion, up 17.1% year-over-year
  • Net Income After Tax: JPY 118.6 billion, up 19.6% year-over-year
  • Operating Margin: 52.8%, an increase of 2.4 percentage points

Market Reaction#

Despite the strong earnings, Chugai's stock closed at JPY 8,926, down 0.91% in after-hours trading. This decline suggests that investors may be cautious about the company's future growth potential or external market conditions. The stock is currently trading at a high price-to-earnings (P/E) ratio of 33.43, which could be contributing to investor hesitance. Over the past six months, the stock has delivered a notable return of 29.81%, although it is considered to be trading above its fair value.

Outlook & Guidance#

Chugai remains optimistic about its future, expecting continued growth from new product launches and strategic partnerships. The company has set revenue forecasts for FY2026 and FY2027 at JPY 8,615.26 million and JPY 9,383.77 million, respectively. Executives emphasized the importance of ongoing investments in research and development to sustain long-term growth and expand their product portfolio.